Comparative analyses of overall survival in patients with anaplastic lymphoma kinase‐positive and matched wild‐type advanced nonsmall cell lung cancer

摘要: BACKGROUND: The purpose of this study was to investigate the overall survival (OS) patients with advanced ALK-positive nonsmall cell lung cancer (NSCLC) who were managed in pre-ALK inhibitor era and compare their that a matched case cohort ALK wild-type (WT) patients. METHODS: Data from 1166 had stage IIIB/IV NSCLC nonsquamous histology collected database Seoul National University Hospital between 2003 2009. fluorescence situ hybridization (FISH) used analyze 262 either WT epidermal growth factor receptor (EGFR) or nonresponders previous EGFR tyrosine kinase (TKI) therapy. Overall compared 3 groups: 1) patients, 2) mutation-positive 3) ALK-WT/EGFR-WT patients. Progression-free (PFS) after first-line chemotherapy TKIs also analyzed. RESULTS: Twenty-three according FISH analysis did not receive inhibitors during follow-up. The median OS for WT/WT 12.2 months, 29.6 19.3 respectively (vs P = .001; vs WT/WT, .127). PFS groups different. However, received shorter other 2 < .021). CONCLUSIONS: In era, experienced shortest survival, although it differ statistically Although responses platinum-based different comparator groups, even more resistant TKI treatment than Cancer 2012;3579–3586. © 2011 American Society.